Clinical Trial Update: Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial of isatuximab in T-cell precursor acute leukemia/lymphoblastic lymphoma-leukemia was terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia
• T-lymphoblastic Lymphoma Leukemia

Drugs mentioned

• Isatuximab (isatuximab)

Snippet

Sponsor: Sanofi | Conditions: T-cell Type Acute Leukemia-Precursor, T-lymphoblastic Lymphoma/Leukaemia | Phase 2 | Status: TERMINATED | Results posted: 2020-01-18